Corcept Therapeutics Incorporated

CORT

US2183521028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
28.62 ^USD	-0.62%		+2.84%	-11.88%

05-16	Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	MT
05-02	Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	MT

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Fiscal 2022

February 15, 2022 at 09:05 pm

Corcept Therapeutics Incorporated provided revenue guidance for the fiscal 2022. For the year, the company expects revenue guidance in the range of $400 million - $430 million.

Latest news about Corcept Therapeutics Incorporated

Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	05-16	MT
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	05-02	MT
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	05-01	MT
Transcript : Corcept Therapeutics Incorporated, Q1 2024 Earnings Call, May 01, 2024	05-01
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	04-29	CI
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	04-22	CI
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	04-15	CI
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	04-08	CI
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	04-01	CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	03-21	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	02-16	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	02-16	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	02-16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	02-16	MT
Sector Update: Health Care	02-16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	02-15	MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	02-15	CI
Transcript : Corcept Therapeutics Incorporated, Q4 2023 Earnings Call, Feb 15, 2024	02-15
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial	02-15	CI
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology	01-29	CI
Corcept Therapeutics Sees 31% Increase in Q4 Revenue, Issues 2024 Revenue Guidance	01-08	MT
Corcept Therapeutics Incorporated announces an Equity Buyback for $200 million worth of its shares.	01-08	CI

Chart Corcept Therapeutics Incorporated

Duration

Period

More charts

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Companyâs portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Corcept Therapeutics Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.62 USD

Average target price

43.6 USD

Spread / Average Target

+52.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CORCEPT THERAPEUTICS INCORPORATED	-11.88%	2.98B
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	208B
ROCHE HOLDING AG	-5.15%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals